10% Owner Coastlands Buys $319K of Bolt Biotherapeutics Stock
BOLT has more than doubled off its 52-week low of $3.1.
Summary
Coastlands Capital LP, a 10% owner of Bolt Biotherapeutics, bought 50,000 shares at a weighted-average $6.38 for about $319,000, lifting its stake to 462,416 shares.
Key Events · Ownership and Investor Activity · BOLT
-
10% Owner Buys $319K of Stock
On 2026-11-09, Coastlands Capital LP purchased 50,000 shares at a weighted-average $6.38, for a total of $319,000.
-
Stake Rises to 462,416 Shares
Post-transaction indirect holdings via Coastlands Capital LP stand at 462,416 shares.
-
Follows $120M Prana Deal
The buy follows Bolt's announced acquisition of Prana Therapies and concurrent $120 million private placement, disclosed 2026-10-23.
-
Against Net Insider Selling
Over the prior 90 days insiders were net sellers of about $123,839, mostly tax-withholding sales, making this open-market buy a counter-trend move.
Analysis · BOLT · Life Sciences
Coastlands Capital LP, a 10% owner, put $319,000 of real money into BOLT at a weighted-average $6.38 per share — an open-market purchase, not an option exercise or grant. For a company this small, that is a meaningful bet, and it lands just weeks after Bolt announced its Prana Therapies acquisition and $120 million private placement, a deal management says is needed to push PRA-216 forward. Because the buyer is a financial investor adding to a position rather than an operator, the signal carries less weight than a CEO buy would — but it is still the largest insider open-market buy in the recent record, against a 90-day backdrop of net insider selling.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BOLT was trading at $6.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12M. The 52-week trading range was $3.10 to $7.78. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.